Related Experiment Video
Updated: Jan 15, 2026
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.0K
SGLT-2 Inhibitors After Acute Coronary Syndrome As Preventive Approach for Heart Failure-Related Complications: A
Daniel Paulino-Gonzalez1, Miguel A Pardiño-Vega2, Edwin Andrade-Arbaiza3
1Facultad de Medicina, Universidad Autónoma Metropolitana- Unidad Xochimilco, Mexico, Mexico.
American Journal of Therapeutics
|October 9, 2025
Summary
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalizations, cardiac death, and stroke risk in patients post-acute coronary syndrome. These findings highlight SGLT-2 inhibitors
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are established heart failure (HF) treatments.
- Their benefit in preventing major adverse cardiovascular events post-acute coronary syndrome (ACS) is not well-defined.
Purpose of the Study:
- To evaluate the efficacy of SGLT-2 inhibitors in improving cardiovascular outcomes for patients following ACS.
Main Methods:
- A meta-analysis of 10 studies (7 RCTs, 3 cohort studies) involving 15,114 patients post-ACS.
- Included patients had risk factors for HF hospitalization or adverse cardiovascular events.
- Compared SGLT-2 inhibitor initiation post-ACS versus placebo.
Main Results:
- SGLT-2 inhibitors significantly reduced first HF hospitalization (RR=0.78) and stroke risk (RR=0.56).
- A significant reduction in cardiac death was observed (RR=0.84), primarily from observational data.
- No significant effect on all-cause mortality; empagliflozin showed benefit for HF hospitalization, dapagliflozin did not.
Conclusions:
- SGLT-2 inhibitors are beneficial in post-ACS management, reducing HF hospitalization, cardiac death, and stroke.
- Specific agents like empagliflozin demonstrate efficacy in HF prevention post-ACS.
Related Concept Videos
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:22Heart Failure Drugs: β-Blockers
770
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
770
01:26Coronary Artery Disease IV: Preventive Measures
589
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
589
01:28Acute Coronary Syndrome IV: Interprofessional Care
219
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219